What is the difference between NAD and NADP?

One phosphate group — 80 daltons, on the adenine half's ribose, away from the reactive nicotinamide ring.

Why does the cell need both?

Catabolism and anabolism need opposite redox conditions simultaneously. One shared pool could not be oxidised and reduced at once.

Which one is the antioxidant cofactor?

NADPH. Antioxidant systems run on the reduced NADP pool, not on NADH.

NAD+

Eighty Daltons Apart, and Metabolically Opposed

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

NADP differs from NAD by a single phosphate group: 743.4 Da against 663.4, a difference of exactly 80. Despite that near-identity the two run opposite kinds of chemistry — NAD/NADH in catabolism, NADP/NADPH in biosynthesis and antioxidant defence.

Key facts

NAD+: 663.4 Da, C21H27N7O14P2, CID 5892
NADP+: 743.4 Da, C21H28N7O17P3, CID 5885
Difference: 80.0 Da — one HPO3
NADPH: 745.4 Da, C21H30N7O17P3, CID 5884
Converting enzyme: NAD+ kinase
NAD/NADH role: Catabolism — energy extraction
NADP/NADPH role: Anabolism and antioxidant defence

The arithmetic, which checks out exactly

NAD+ is C21H27N7O14P2 at 663.4 Da. NADP+ is C21H28N7O17P3 at 743.4. The formula difference is one hydrogen, three oxygens and one phosphorus — HPO3, at 79.98 — and the mass difference is 80.0. NADP is NAD with a phosphate added, and the numbers say so precisely.

Where the phosphate sits and why it matters

On the adenine half's ribose, well away from the nicotinamide ring that does the redox chemistry. So the reactive end is unchanged and the recognition end is completely altered. Enzymes distinguish the two cofactors by that phosphate, which is what allows a cell to run two independent pools of what is chemically almost the same molecule.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

Why running two pools is the point

Catabolism and anabolism happen simultaneously in the same cell and need opposite redox conditions — one to extract electrons from fuel, the other to supply electrons for building. A single shared pool could not be oxidised and reduced at once. Two pools, distinguished by one phosphate, let both operate independently in the same cytoplasm.

How the cell keeps them opposed

NAD is kept largely oxidised, ready to accept electrons from fuel molecules. NADP is kept largely reduced, ready to donate them to biosynthesis and to antioxidant systems. Those are opposite steady states maintained deliberately, and the ratio in each pool is a controlled quantity rather than an incidental one.

The single enzyme connecting them

NAD+ kinase phosphorylates NAD+ to make NADP+, reviewed by McGuinness in the International Journal of Biochemistry in 1985. One enzyme is the entire bridge between the two systems, which makes it the control point determining how much of the cell's total nicotinamide dinucleotide sits in each pool.

Why this matters for reading anything about NAD

Because claims about NAD frequently drift between the two without saying so. Antioxidant defence runs on NADPH, not NADH. Energy extraction runs on NAD+, not NADP+. A statement about one is not a statement about the other, and the eighty-dalton difference is doing a great deal of work.

Quick reference

	NAD+/NADH	NADP+/NADPH
Mass, oxidised form	663.4 Da	743.4 Da
Kept mostly	Oxidised	Reduced
Serves	Catabolism	Anabolism, antioxidant defence
PubChem CID	5892	5885

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What is the difference between NAD and NADP?: One phosphate group — 80 daltons, on the adenine half's ribose, away from the reactive nicotinamide ring.
Why does the cell need both?: Catabolism and anabolism need opposite redox conditions simultaneously. One shared pool could not be oxidised and reduced at once.
Which one is the antioxidant cofactor?: NADPH. Antioxidant systems run on the reduced NADP pool, not on NADH.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum